$PVCT CEO Letter: Final MM P2 PV-10 data presented, Systemic immune response shown in multiple cancers

The takeaways appear to be:

• Final MM Phase 2 data finally was reported in 2012,
• Murine study data, via Moffitt, showed PV-10's systemic, anti-tumor immune response,
• This systemic immune response was shown in multiple cancers (i.e., melanoma, lung, breast),
• Combination therapy complementariness of PV-10 and "ipi," and
• Potentially year-end completion for the expanded HCC Phase 1 trial.

A question: Will Dr. Rosemurgy be the PI for a pancreas P1 trial?

$PVCT: The Southeastern Center for Digestive Disorders & Pancreatic Cancer (2nd Liver Cancer/HCC Trial Site)

The website of The Southeastern Center for Digestive Disorders & Pancreatic Cancer can be found here. The principal investigator is Dr. Alexander Rosemurgy, MD. As a side note, Dr. Paul Toomey, MD of Moffitt fame (he was quoted several times related to Moffitt's poster at SSO in March 2012 when the cancer research center first concluded publicly that "Intralesional PV-10 Treatment Leads to the Induction of Anti-Tumor Immunity") appears to be doing a fellowship at The Southeastern Center (see below).